| Recruiting | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma | Phase 3 | 2025-08-06 |
| Active Not Recruiting | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Blad Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 3 | 2024-08-29 |
| Recruiting | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter | — | 2023-11-17 |
| Completed | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIB Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder | Phase 1 | 2022-06-01 |
| Active Not Recruiting | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 3 | 2022-03-01 |
| Completed | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 3 | 2021-11-30 |
| Terminated | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 3 | 2021-02-19 |
| Withdrawn | Efficacy and Safety of UGN-101 in Recurrent Patients Carcinoma, Transitional Cell Carcinoma, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 3 | 2019-10-01 |
| Completed | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | 2018-10-15 |
| Completed | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis | Phase 3 | 2017-04-04 |
| Withdrawn | Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulat Overactive Bladder | Phase 1 / Phase 2 | 2016-10-01 |
| Completed | Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients Bladder Cancer, Neoplasms, Urinary Bladder Diseases | Phase 2 | 2014-12-01 |
| Terminated | Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients Overactive Bladder | Phase 1 / Phase 2 | 2014-07-01 |
| Completed | Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients Interstitial Cystitis, IC | Phase 1 / Phase 2 | 2013-11-01 |
| Completed | Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC Carcinoma of Urinary Bladder, Superficial | N/A | 2013-06-01 |
| Withdrawn | A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instil Non Muscle Invasive Bladder Cancer | N/A | 2013-03-01 |
| Completed | Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in Urinary Bladder Neoplasms, Urologic Neoplasms, Neoplasms | N/A | 2013-01-01 |
| Completed | Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug R Carcinoma of Urinary Bladder, Invasive | N/A | 2011-11-01 |
| Available | Named Patient Program for Mitomycin for Pyelocalyceal Solution Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter | — | — |